GENELUX Corp
Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat tumor types. The company trades on The Stock Market LLC and maintains its website at genelux.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GENELUX Corp does
In the company’s own words
Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat tumor types. The company trades on The Stock Market LLC and maintains its website at genelux.com.
The company's lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of vaccinia virus designed to selectively kill tumor cells while inducing a robust immune response against patient tumor neoantigens. Olvi-Vec represents an "off-the-shelf" personalized immunotherapy approach, where the same viral product administered to different patients generates cellular immune responses specific to each patient's unique neoantigens. The company is executing a late-stage clinical program evaluating Olvi-Vec across three ongoing trials: a Phase 3 registrational trial in the United States for platinum-resistant/refractory ovarian cancer, a Phase 2 trial in the United States for recurrent non-small cell lung cancer, and a Phase 1b/2 trial in China for recurrent small cell lung cancer.
Genelux developed its proprietary CHOICE discovery platform, which enables rapid development of oncolytic vaccinia virus immunotherapy candidates. The company has generated an extensive portfolio containing over 500 different versions of vaccinia virus armed with more than 110 transgenes possessing various engineered immune modulatory and tumor cell-killing properties.
The company operates a cGMP manufacturing facility in San Diego, California, producing clinical trial material and intended commercial supply. Genelux also leases a second building at the same location for laboratory capabilities and administrative offices. In September 2021, the company entered into a license agreement with Newsoara BioPharma granting exclusive rights to develop and commercialize Olvi-Vec in mainland China, Taiwan, Hong Kong, and Macau, with potential milestone payments up to $160.5 million and royalties on net sales.
As a smaller reporting company, Genelux has incurred significant losses since inception and anticipates continued losses as it advances its clinical development programs. The company's intellectual property portfolio consists of 12 issued United States patents, 9 issued foreign patents, and 7 pending foreign patent applications relating to product composition, methods of use, and manufacturing processes, with issued patents expected to expire between 2026 and 2038.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WESTLAKE VILLAGE, CA
- Fiscal year end
- December
- CIK
- 1231457
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GENELUX Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GENELUX Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GENELUX Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GENELUX Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GENELUX Corp's last four quarterly filings that the numbers alone won't show?”